期刊文献+

免疫组织化学法检测子宫颈组织p16蛋白表达的石蜡切片厚度探讨 被引量:3

Paraffin section thickness in immunohistochemical detection of p16 expression in cervical tissue samples
下载PDF
导出
摘要 目的:探讨免疫组织化学法检测子宫颈组织中p16蛋白表达时的石蜡切片厚度。方法:收集2014年1月至2018年3月中山市博爱医院病理检查结果为慢性宫颈炎(150例)、低级别鳞状上皮内病变(LSIL,126例)、高级别鳞状上皮内病变(HSIL,96例)及宫颈癌(78例)患者的子宫颈组织标本进行p16免疫组织化学染色,并采用条件Logistic回归分析石蜡切片厚度为2. 0、3. 0、4. 0、5. 0、6. 0μm的标本p16蛋白表达的差异。结果:随着切片厚度增加,病变部位所在细胞核p16蛋白染色逐渐加深。慢性宫颈炎和宫颈癌患者标本不同切片厚度的p16蛋白阳性率差异无统计学意义(χ~2=7. 817和1. 332,均P> 0. 05);而LSIL和HSIL患者标本不同切片厚度的p16蛋白阳性率差异有统计学意义(χ~2=17. 688和10. 182,P <0. 05或P <0. 01),当标本切片厚度为3. 0~5. 0μm时可获得较为稳定而可靠的检测结果。结论:免疫组织化学法行子宫颈组织p16蛋白检测推荐的标本切片厚度为3. 0~5. 0μm。 Objective: To investigate paraffin section thickness in immunohistochemical detection of p16 expression in cervical tissue samples. Methods: p16 immunohistochemical staining was performed in 150 cases of chronic cervicitis,126 cases of low-grade squamous intraepithelial lesions( LSIL),96 cases of high-grade squamous intraepithelial lesions( HSIL) and 78 cases of cervical cancer from January2014 to March 2018 in Zhongshan Boai Hospital. The results of p16 protein expression in paraffin sections with thickness of 2,3,4,5 and 6 μm were compared using Logistic regression analysis. Results: With the increase of slice thickness,the staining of p16 protein in nucleus gradually increased. The thickness of cervical slices in chronic cervicitis and cervical cancer samples had no significant effect on the positive rate of p16 protein( χ^2= 7. 817 and 1. 332,both P > 0. 05),while the thickness of slices in LSIL and HSIL samples had significant effect on the positive rate of p16 protein( χ^2=17. 688 and 10. 182,P < 0. 05 or P < 0. 01). The stable and reliable results were obtained when the slices were between 3 and 5 μm thick. Conclusion: Paraffin sections with thickness of 3. 0-5. 0 μm are recommended for immnohistochemical staining of p16 protein in cervical tissue samples.
作者 陈志强 米贤军 陈昂 段立锋 代新珍 邓文同 CHEN Zhiqiang;MI Xianjun;CHEN Ang;DUAN Lifeng;DAI Xinzhen;DENG Wentong(Department of Pathology,Zhongshan Boai Hospital Affiliated to Southern Medical University,Zhongshan 528400,Guangdong Province,China)
出处 《浙江大学学报(医学版)》 CAS CSCD 北大核心 2018年第4期362-366,共5页 Journal of Zhejiang University(Medical Sciences)
基金 广东省医学科研基金(A2017321) 中山市社会公益科技研究专项资金(2018B1035) 中山市卫生和计划生育局医学科研立项课题(2014J128) 中山市卫生和计划生育局医学科研课题(2017J111)
关键词 宫颈肿瘤/病理学 宫颈肿瘤/诊断 鳞状细胞/病理学 免疫组织化学 基因 p16 石蜡包埋 显微切片术 Uterine cervical neoplasms/pathology Uterine cervical neoplasms/ diagnosis Carcinoma,squamous cell/pathology Immunohistochemistry Genes,p16 Paraffin embedding Microtomy
  • 相关文献

参考文献4

二级参考文献24

  • 1曾瑄,梁智勇,武莎斐,周炜洵,高洁,刘彤华.乳腺癌HER2蛋白表达阳性者的基因状态分析[J].中华病理学杂志,2006,35(10):584-588. 被引量:40
  • 2程淑霞,赵先兰.宫颈癌及癌前病变中p16^(INK4A)与HPV的关系[J].国外医学(妇产科学分册),2006,33(5):317-320. 被引量:8
  • 3Schildhaus HU, Schroeder L, Merkelbach-Bruse S, et al. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes [ J]. The Breast, 2013, 22(6) :1066-1071. 被引量:1
  • 4Downey L, Livingston RB, Koehler M, eta/. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paelitaxel in metastatic breast cancer [ J 1- Clin Cancer Res, 2010, 16(4) :1281-1288. 被引量:1
  • 5Hanna WM, Rtischoff J, Bilous M, et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity[ J]. Modern Pathology, 2014, 27 (1) : 4-18. 被引量:1
  • 6Pritehard KI, Munro A, O'Malley FP, et al. Chromosome 17 eentromere (CEP17) duplication as a predictor of anthraeycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial[J]. Breast Cancer Res Treat, 2012, 131(2) : 541-551. 被引量:1
  • 7Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline update[ J]. J Clin Oneol, 2013,31 (31) :3997-4013. 被引量:1
  • 8Fountzilas G, Christodoulou C, Bobos M, et al. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab [ J ]. Journal of translational medicine, 2012,10 ( 1 ) : 212. 被引量:1
  • 9Fountzilas G, Dafni U, Bobos M, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group ( HeCOG ) phase 111 trims [ J ]. BMC cancer, 2013,13(1) :163. 被引量:1
  • 10Zhang H, Ren G, Wang X, et al. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases[ J]. Breast cancer research and treatment, 2012, 134(2) : 743-749. 被引量:1

共引文献110

同被引文献28

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部